NO332361B1 - Pyrrolo(3,4-c)pyrazolderivater, fremgangsmate for fremstilling og anvendelse derav, farmasoytisk sammensetning, samt produkt eller sett - Google Patents

Pyrrolo(3,4-c)pyrazolderivater, fremgangsmate for fremstilling og anvendelse derav, farmasoytisk sammensetning, samt produkt eller sett Download PDF

Info

Publication number: NO332361B1
Authority: NO; Norway
Prior art keywords: formula; tetrahydropyrrolo; pyrazol; phenylethanoyl; compound
Prior art date: 2003-07-09

Application number

NO20060113A

Other languages

English (en)

Norwegian (no)

Other versions

NO20060113L (no

Inventor

Mario Varasi

Daniele Fancelli

Paola Vianello

Barbara Forte

Jurgen Moll

Original Assignee

Nerviano Medical Sciences Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-09

Filing date

2006-01-06

Publication date

2012-09-03

2006-01-06 Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl

2006-04-05 Publication of NO20060113L publication Critical patent/NO20060113L/no

2012-09-03 Publication of NO332361B1 publication Critical patent/NO332361B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 24
238000002360 preparation method Methods 0.000 title claims abstract description 12
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
230000008569 process Effects 0.000 title abstract description 3
QBMRFAZXVYJCCO-UHFFFAOYSA-N pyrrolo[3,4-c]pyrazole Chemical class N1=NC=C2C=NC=C21 QBMRFAZXVYJCCO-UHFFFAOYSA-N 0.000 title abstract 2
239000000825 pharmaceutical preparation Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 122
206010028980 Neoplasm Diseases 0.000 claims abstract description 23
150000003839 salts Chemical class 0.000 claims abstract description 23
201000011510 cancer Diseases 0.000 claims abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
102000001253 Protein Kinase Human genes 0.000 claims abstract description 10
230000000694 effects Effects 0.000 claims abstract description 10
108060006633 protein kinase Proteins 0.000 claims abstract description 10
238000011282 treatment Methods 0.000 claims abstract description 8
-1 fluoromethylene Chemical group 0.000 claims description 26
238000006243 chemical reaction Methods 0.000 claims description 24
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
239000001257 hydrogen Substances 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 12
108090000461 Aurora Kinase A Proteins 0.000 claims description 11
102100032311 Aurora kinase A Human genes 0.000 claims description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
230000002062 proliferating effect Effects 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
208000035475 disorder Diseases 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
125000005843 halogen group Chemical group 0.000 claims description 8
125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 8
102000003989 Aurora kinases Human genes 0.000 claims description 7
108090000433 Aurora kinases Proteins 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 5
239000002246 antineoplastic agent Substances 0.000 claims description 5
KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 5
230000004663 cell proliferation Effects 0.000 claims description 5
229940127089 cytotoxic agent Drugs 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
ABWUHZJWSBGALY-RUZDIDTESA-N 4-(4-cyclopropylpiperazin-1-yl)-n-[5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N(CC1)CCN1C1CC1 ABWUHZJWSBGALY-RUZDIDTESA-N 0.000 claims description 4
DQZIXCNNUYBJFM-XMMPIXPASA-N 4-(4-ethylpiperazin-1-yl)-n-[5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide Chemical compound C1CN(CC)CCN1C1=CC=C(C(=O)NC=2C=3CN(CC=3NN=2)C(=O)[C@H](OC)C=2C=CC=CC=2)C=C1 DQZIXCNNUYBJFM-XMMPIXPASA-N 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
208000031481 Pathologic Constriction Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
201000005787 hematologic cancer Diseases 0.000 claims description 4
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
125000005842 heteroatom Chemical group 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
BLYXADULVCOALU-RUZDIDTESA-N n-[5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-propan-2-ylpiperazin-1-yl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C(C)C)CC1 BLYXADULVCOALU-RUZDIDTESA-N 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 4
230000036262 stenosis Effects 0.000 claims description 4
208000037804 stenosis Diseases 0.000 claims description 4
210000001685 thyroid gland Anatomy 0.000 claims description 4
230000002792 vascular Effects 0.000 claims description 4
WGHIJJDQGIWJHO-VCUSLETLSA-N 4-(3,4-dimethylpiperazin-1-yl)-n-[5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)C(C)C1 WGHIJJDQGIWJHO-VCUSLETLSA-N 0.000 claims description 3
CAQRLZFEWBTCCO-GOSISDBHSA-N 4-(4-methylpiperazin-1-yl)-n-[5-[(2r)-2-phenylpropanoyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide Chemical compound O=C([C@H](C)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 CAQRLZFEWBTCCO-GOSISDBHSA-N 0.000 claims description 3
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
201000009030 Carcinoma Diseases 0.000 claims description 3
206010018364 Glomerulonephritis Diseases 0.000 claims description 3
208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
208000009905 Neurofibromatoses Diseases 0.000 claims description 3
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
201000010208 Seminoma Diseases 0.000 claims description 3
230000002378 acidificating effect Effects 0.000 claims description 3
210000003169 central nervous system Anatomy 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
230000003325 follicular Effects 0.000 claims description 3
201000001441 melanoma Diseases 0.000 claims description 3
UALDPXIJMSKZPM-HSZRJFAPSA-N n-[5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]-4-piperidin-1-ylbenzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCCCC1 UALDPXIJMSKZPM-HSZRJFAPSA-N 0.000 claims description 3
201000004931 neurofibromatosis Diseases 0.000 claims description 3
201000008968 osteosarcoma Diseases 0.000 claims description 3
210000001428 peripheral nervous system Anatomy 0.000 claims description 3
208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
208000001608 teratocarcinoma Diseases 0.000 claims description 3
OOVDVPOUMZDRSK-QGZVFWFLSA-N 4-(4-fluoropiperidin-1-yl)-n-[5-[(2r)-2-phenylpropanoyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide Chemical compound O=C([C@H](C)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCC(F)CC1 OOVDVPOUMZDRSK-QGZVFWFLSA-N 0.000 claims description 2
NAPSHPDIOJOSTK-RUZDIDTESA-N 4-(4-tert-butylpiperazin-1-yl)-n-[5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C(C)(C)C)CC1 NAPSHPDIOJOSTK-RUZDIDTESA-N 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
230000000259 anti-tumor effect Effects 0.000 claims description 2
238000011319 anticancer therapy Methods 0.000 claims description 2
206010003246 arthritis Diseases 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
229940098779 methanesulfonic acid Drugs 0.000 claims description 2
KGHHVSJZWGWWDG-JOCHJYFZSA-N n-[5-[(2r)-2-hydroxy-2-phenylacetyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)NC=2C=3CN(CC=3NN=2)C(=O)[C@H](O)C=2C=CC=CC=2)C=C1 KGHHVSJZWGWWDG-JOCHJYFZSA-N 0.000 claims description 2
208000015122 neurodegenerative disease Diseases 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
150000003512 tertiary amines Chemical class 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
JPCXLKGPBVAGHQ-QGZVFWFLSA-N 4-morpholin-4-yl-n-[5-[(2r)-2-phenylpropanoyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide Chemical compound O=C([C@H](C)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCOCC1 JPCXLKGPBVAGHQ-QGZVFWFLSA-N 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
208000023275 Autoimmune disease Diseases 0.000 claims 1
201000006107 Familial adenomatous polyposis Diseases 0.000 claims 1
208000036142 Viral infection Diseases 0.000 claims 1
208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 1
230000009385 viral infection Effects 0.000 claims 1
201000010099 disease Diseases 0.000 abstract description 4
238000002560 therapeutic procedure Methods 0.000 abstract description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
210000004027 cell Anatomy 0.000 description 23
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
238000005160 1H NMR spectroscopy Methods 0.000 description 17
239000000203 mixture Substances 0.000 description 17
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000000243 solution Substances 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
239000003112 inhibitor Substances 0.000 description 12
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
230000002401 inhibitory effect Effects 0.000 description 11
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
239000002904 solvent Substances 0.000 description 10
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 9
239000000758 substrate Substances 0.000 description 9
238000007796 conventional method Methods 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000022131 cell cycle Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
VUWAGENLXQIUJY-UHFFFAOYSA-N 5-o-tert-butyl 1-o-ethyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2=C1C(N)=NN2C(=O)OCC VUWAGENLXQIUJY-UHFFFAOYSA-N 0.000 description 4
208000020584 Polyploidy Diseases 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
239000000047 product Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108010033040 Histones Proteins 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
150000001263 acyl chlorides Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
239000003909 protein kinase inhibitor Substances 0.000 description 3
GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical class N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 description 3
238000010992 reflux Methods 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
239000003643 water by type Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
YLYRHIITRIEACU-UHFFFAOYSA-N 5-o-tert-butyl 1-o-ethyl 3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate Chemical compound C1=2CN(C(=O)OC(C)(C)C)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 YLYRHIITRIEACU-UHFFFAOYSA-N 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
102100026379 Neurofibromin Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
201000006083 Xeroderma Pigmentosum Diseases 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
239000004037 angiogenesis inhibitor Substances 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
230000007257 malfunction Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
208000015768 polyposis Diseases 0.000 description 2
238000010837 poor prognosis Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000003039 volatile agent Substances 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
DIWVBIXQCNRCFE-MRVPVSSYSA-N (2r)-2-methoxy-2-phenylacetic acid Chemical compound CO[C@@H](C(O)=O)C1=CC=CC=C1 DIWVBIXQCNRCFE-MRVPVSSYSA-N 0.000 description 1
KUKSPRRZVLBAEX-MRVPVSSYSA-N (2r)-2-methoxy-2-phenylacetyl chloride Chemical compound CO[C@@H](C(Cl)=O)C1=CC=CC=C1 KUKSPRRZVLBAEX-MRVPVSSYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
VGFVZLRQMPEEEW-UHFFFAOYSA-N 1-phenylpiperazin-2-amine Chemical compound NC1CNCCN1C1=CC=CC=C1 VGFVZLRQMPEEEW-UHFFFAOYSA-N 0.000 description 1
DVUZOJFIDIXNQD-UHFFFAOYSA-N 1-phenylpiperidin-2-amine Chemical class NC1CCCCN1C1=CC=CC=C1 DVUZOJFIDIXNQD-UHFFFAOYSA-N 0.000 description 1
XAEGRAIWWBXIRR-UHFFFAOYSA-N 1h-pyrazol-5-ylurea Chemical class NC(=O)NC=1C=CNN=1 XAEGRAIWWBXIRR-UHFFFAOYSA-N 0.000 description 1
MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
AEXOSHOHHKSIKO-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)benzoyl chloride;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1C1=CC=CC=C1C(Cl)=O AEXOSHOHHKSIKO-UHFFFAOYSA-N 0.000 description 1
BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
LZTPJGBYVKLMTF-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-n-[5-(2-phenylacetyl)-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)NC2=C3CN(CC3=NN2)C(=O)CC=2C=CC=CC=2)C=C1 LZTPJGBYVKLMTF-UHFFFAOYSA-N 0.000 description 1
UCFZVQHKTRSZMM-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)benzoic acid Chemical compound C1CN(C)CCN1C1=CC=C(C(O)=O)C=C1 UCFZVQHKTRSZMM-UHFFFAOYSA-N 0.000 description 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
229940123587 Cell cycle inhibitor Drugs 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
102000005454 Dimethylallyltranstransferase Human genes 0.000 description 1
108010006731 Dimethylallyltranstransferase Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241001032544 Galearctus aurora Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
DZJXKISLUDYJSV-UHFFFAOYSA-N [N].C1CCNC1 Chemical group [N].C1CCNC1 DZJXKISLUDYJSV-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000002942 anti-growth Effects 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000003719 aurora kinase inhibitor Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003793 centrosome Anatomy 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
ASJRBDVBMSSGGH-UHFFFAOYSA-N ethyl 3-[(4-piperidin-1-ylbenzoyl)amino]-5,6-dihydro-4h-pyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CNCC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCCCC1 ASJRBDVBMSSGGH-UHFFFAOYSA-N 0.000 description 1
JFOMPAYAJHGOFP-UHFFFAOYSA-N ethyl 3-[[4-(3,4-dimethylpiperazin-1-yl)benzoyl]amino]-5,6-dihydro-4h-pyrrolo[3,4-c]pyrazole-1-carboxylate;trihydrochloride Chemical compound Cl.Cl.Cl.C1=2CNCC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C)C(C)C1 JFOMPAYAJHGOFP-UHFFFAOYSA-N 0.000 description 1
POEAJWMZETVKLL-NBXNUCLWSA-N ethyl 3-[[4-(3,4-dimethylpiperazin-1-yl)benzoyl]amino]-5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](OC)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C)C(C)C1 POEAJWMZETVKLL-NBXNUCLWSA-N 0.000 description 1
HCSYZCLWAPPELH-BPGUCPLFSA-N ethyl 3-[[4-(3,4-dimethylpiperazin-1-yl)benzoyl]amino]-5-[(2r)-2-phenylpropanoyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](C)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C)C(C)C1 HCSYZCLWAPPELH-BPGUCPLFSA-N 0.000 description 1
SBHTWSZKUGLUER-UHFFFAOYSA-N ethyl 3-[[4-(4-cyclopropylpiperazin-1-yl)benzoyl]amino]-5,6-dihydro-4h-pyrrolo[3,4-c]pyrazole-1-carboxylate;trihydrochloride Chemical compound Cl.Cl.Cl.C1=2CNCC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N(CC1)CCN1C1CC1 SBHTWSZKUGLUER-UHFFFAOYSA-N 0.000 description 1
CUBKXKYMSJGWJU-HHHXNRCGSA-N ethyl 3-[[4-(4-cyclopropylpiperazin-1-yl)benzoyl]amino]-5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](OC)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N(CC1)CCN1C1CC1 CUBKXKYMSJGWJU-HHHXNRCGSA-N 0.000 description 1
IYWINYNULQKAMB-OAQYLSRUSA-N ethyl 3-[[4-(4-cyclopropylpiperazin-1-yl)benzoyl]amino]-5-[(2r)-2-phenylpropanoyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](C)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N(CC1)CCN1C1CC1 IYWINYNULQKAMB-OAQYLSRUSA-N 0.000 description 1
CRRIRVXAXXHIBD-AREMUKBSSA-N ethyl 3-[[4-(4-ethylpiperazin-1-yl)benzoyl]amino]-5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](OC)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(CC)CC1 CRRIRVXAXXHIBD-AREMUKBSSA-N 0.000 description 1
OSSPNIDOSROHLB-OAQYLSRUSA-N ethyl 3-[[4-(4-ethylpiperazin-1-yl)benzoyl]amino]-5-[(2r)-2-phenylpropanoyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](C)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(CC)CC1 OSSPNIDOSROHLB-OAQYLSRUSA-N 0.000 description 1
LZTAPKOVTUCSGA-UHFFFAOYSA-N ethyl 3-[[4-(4-fluoropiperidin-1-yl)benzoyl]amino]-5,6-dihydro-4h-pyrrolo[3,4-c]pyrazole-1-carboxylate;trihydrochloride Chemical compound Cl.Cl.Cl.C1=2CNCC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCC(F)CC1 LZTAPKOVTUCSGA-UHFFFAOYSA-N 0.000 description 1
CSHVDQTUSVGGJU-RUZDIDTESA-N ethyl 3-[[4-(4-fluoropiperidin-1-yl)benzoyl]amino]-5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](OC)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCC(F)CC1 CSHVDQTUSVGGJU-RUZDIDTESA-N 0.000 description 1
IPXRCFBGFILGEX-LJQANCHMSA-N ethyl 3-[[4-(4-fluoropiperidin-1-yl)benzoyl]amino]-5-[(2r)-2-phenylpropanoyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](C)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCC(F)CC1 IPXRCFBGFILGEX-LJQANCHMSA-N 0.000 description 1
MCMIAXSPMVKOLG-UHFFFAOYSA-N ethyl 3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-5,6-dihydro-4h-pyrrolo[3,4-c]pyrazole-1-carboxylate;trihydrochloride Chemical compound Cl.Cl.Cl.C1=2CNCC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 MCMIAXSPMVKOLG-UHFFFAOYSA-N 0.000 description 1
XOXWLEJEEOOPRQ-UHFFFAOYSA-N ethyl 3-[[4-(4-propan-2-ylpiperazin-1-yl)benzoyl]amino]-5,6-dihydro-4h-pyrrolo[3,4-c]pyrazole-1-carboxylate;trihydrochloride Chemical compound Cl.Cl.Cl.C1=2CNCC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C(C)C)CC1 XOXWLEJEEOOPRQ-UHFFFAOYSA-N 0.000 description 1
AHHCVEAVFKVPEA-UHFFFAOYSA-N ethyl 3-[[4-(4-tert-butylpiperazin-1-yl)benzoyl]amino]-5,6-dihydro-4h-pyrrolo[3,4-c]pyrazole-1-carboxylate;trihydrochloride Chemical compound Cl.Cl.Cl.C1=2CNCC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C(C)(C)C)CC1 AHHCVEAVFKVPEA-UHFFFAOYSA-N 0.000 description 1
YLUVVXWBXCIWAN-JOCHJYFZSA-N ethyl 3-[[4-(4-tert-butylpiperazin-1-yl)benzoyl]amino]-5-[(2r)-2-phenylpropanoyl]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](C)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C(C)(C)C)CC1 YLUVVXWBXCIWAN-JOCHJYFZSA-N 0.000 description 1
XPYOBSBAIBJDFH-XMMPIXPASA-N ethyl 5-[(2r)-2-hydroxy-2-phenylacetyl]-3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](O)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XPYOBSBAIBJDFH-XMMPIXPASA-N 0.000 description 1
UGOQPVUYCKGDIB-XMMPIXPASA-N ethyl 5-[(2r)-2-methoxy-2-phenylacetyl]-3-[(4-morpholin-4-ylbenzoyl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](OC)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCOCC1 UGOQPVUYCKGDIB-XMMPIXPASA-N 0.000 description 1
MDSYHOVFEZWNET-RUZDIDTESA-N ethyl 5-[(2r)-2-methoxy-2-phenylacetyl]-3-[(4-piperidin-1-ylbenzoyl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](OC)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCCCC1 MDSYHOVFEZWNET-RUZDIDTESA-N 0.000 description 1
FVOGNNMEGMUHPZ-RUZDIDTESA-N ethyl 5-[(2r)-2-methoxy-2-phenylacetyl]-3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](OC)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 FVOGNNMEGMUHPZ-RUZDIDTESA-N 0.000 description 1
JUOVVKZYLJHWGS-HHHXNRCGSA-N ethyl 5-[(2r)-2-methoxy-2-phenylacetyl]-3-[[4-(4-propan-2-ylpiperazin-1-yl)benzoyl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](OC)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C(C)C)CC1 JUOVVKZYLJHWGS-HHHXNRCGSA-N 0.000 description 1
BXWLTZMIHSVSRM-HXUWFJFHSA-N ethyl 5-[(2r)-2-phenylpropanoyl]-3-[(4-piperidin-1-ylbenzoyl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](C)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCCCC1 BXWLTZMIHSVSRM-HXUWFJFHSA-N 0.000 description 1
HGBKLDQGBUILDV-JOCHJYFZSA-N ethyl 5-[(2r)-2-phenylpropanoyl]-3-[[4-(4-propan-2-ylpiperazin-1-yl)benzoyl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1-carboxylate Chemical compound C1=2CN(C(=O)[C@H](C)C=3C=CC=CC=3)CC=2N(C(=O)OCC)N=C1NC(=O)C(C=C1)=CC=C1N1CCN(C(C)C)CC1 HGBKLDQGBUILDV-JOCHJYFZSA-N 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
239000003906 humectant Substances 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
239000000677 immunologic agent Substances 0.000 description 1
229940124541 immunological agent Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229940045996 isethionic acid Drugs 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229960004393 lidocaine hydrochloride Drugs 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
CGPVXCZGMQFMDS-JOCHJYFZSA-N n-[5-[(2r)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazol-3-yl]-4-morpholin-4-ylbenzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCOCC1 CGPVXCZGMQFMDS-JOCHJYFZSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000013517 stratification Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000003277 telomerase inhibitor Substances 0.000 description 1
BEVRTOCHMXNPLY-UHFFFAOYSA-N tert-butyl 3-amino-4,6-dihydro-1h-pyrrolo[3,4-c]pyrazole-5-carboxylate Chemical compound N1N=C(N)C2=C1CN(C(=O)OC(C)(C)C)C2 BEVRTOCHMXNPLY-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Virology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20060113A 2003-07-09 2006-01-06 Pyrrolo(3,4-c)pyrazolderivater, fremgangsmate for fremstilling og anvendelse derav, farmasoytisk sammensetning, samt produkt eller sett NO332361B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48581403P	2003-07-09	2003-07-09
PCT/EP2004/007515 WO2005005427A1 (fr)	2003-07-09	2004-07-08	Derives du pyrrolo[3,4-c]pyrazole actifs comme inhibiteurs des kinases

Publications (2)

Publication Number	Publication Date
NO20060113L NO20060113L (no)	2006-04-05
NO332361B1 true NO332361B1 (no)	2012-09-03

Family

ID=34062099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060113A NO332361B1 (no)	2003-07-09	2006-01-06	Pyrrolo(3,4-c)pyrazolderivater, fremgangsmate for fremstilling og anvendelse derav, farmasoytisk sammensetning, samt produkt eller sett

Country Status (41)

Country	Link
US (2)	US7141568B2 (fr)
EP (1)	EP1644376B1 (fr)
JP (1)	JP4728232B2 (fr)
KR (1)	KR101075711B1 (fr)
CN (1)	CN100564380C (fr)
AP (1)	AP2214A (fr)
AR (1)	AR050045A1 (fr)
AT (1)	ATE480540T1 (fr)
AU (1)	AU2004255347B2 (fr)
BR (1)	BRPI0411868B8 (fr)
CA (1)	CA2531759C (fr)
CR (1)	CR8171A (fr)
CY (1)	CY1110832T1 (fr)
DE (1)	DE602004029045D1 (fr)
DK (1)	DK1644376T3 (fr)
DO (1)	DOP2004000949A (fr)
EA (1)	EA009462B1 (fr)
EC (1)	ECSP056246A (fr)
ES (1)	ES2349780T3 (fr)
GE (1)	GEP20084395B (fr)
GT (2)	GT200400133A (fr)
HN (1)	HN2004000232A (fr)
IL (1)	IL172923A (fr)
IS (1)	IS2843B (fr)
MA (1)	MA28064A1 (fr)
ME (1)	MEP51908A (fr)
MX (1)	MXPA06000362A (fr)
MY (1)	MY139072A (fr)
NO (1)	NO332361B1 (fr)
NZ (1)	NZ544514A (fr)
PA (1)	PA8606201A1 (fr)
PE (1)	PE20050325A1 (fr)
PL (1)	PL1644376T3 (fr)
PT (1)	PT1644376E (fr)
RS (2)	RS20060004A (fr)
SI (1)	SI1644376T1 (fr)
TN (1)	TNSN06009A1 (fr)
TW (1)	TWI343382B (fr)
UA (1)	UA81682C2 (fr)
WO (1)	WO2005005427A1 (fr)
ZA (1)	ZA200600095B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4555547B2 (ja) *	2000-08-10	2010-10-06	ファイザーイタリアソシエタアレスポンサビリタリミタータ	キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
AU2004276341B2 (en) *	2003-09-23	2011-04-14	Vertex Pharmaceuticals Incorporated	Pyrazolopyrrole derivatives as protein kinase inhibitors
WO2005061519A1 (fr) *	2003-12-19	2005-07-07	Takeda San Diego, Inc.	Inhibiteurs de kinase
US20050250829A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Kinase inhibitors
US7550598B2 (en) *	2004-08-18	2009-06-23	Takeda Pharmaceutical Company Limited	Kinase inhibitors
DE602005023333D1 (de)	2004-10-15	2010-10-14	Takeda Pharmaceutical	Kinaseinhibitoren
KR100919343B1 (ko) *	2005-01-10	2009-09-25	화이자 인코포레이티드	키네이스 억제제로서 피롤로피라졸
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
TW200808311A (en) *	2006-03-30	2008-02-16	Nerviano Medical Sciences Srl	Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (fr) *	2006-08-10	2008-02-14	F. Hoffmann-La Roche Ag	Dérivés de lactame bicycliques, leur fabrication et utilisation en tant qu'agents pharmaceutiques
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
EP2223925A1 (fr) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Inhibiteurs de kinase
JP5547487B2 (ja) *	2006-11-03	2014-07-16	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	抗癌化合物の投与方法
CL2009001158A1 (es) *	2008-05-15	2009-10-23	Nerviano Medical Sciences Srl	Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
JP5518062B2 (ja) *	2008-07-24	2014-06-11	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	オーロラキナーゼ阻害剤および抗悪性腫瘍剤を含む治療用組み合わせ
US20100022553A1 (en) *	2008-07-24	2010-01-28	Nerviano Medical Sciences S.R.L.	Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
WO2010009985A2 (fr)	2008-07-24	2010-01-28	Nerviano Medical Sciences S.R.L.	Combinaison thérapeutique renfermant un inhibiteur de la kinase aurora et des agents antiprolifératifs
ES2468391T3 (es)	2008-12-22	2014-06-16	Millennium Pharmaceuticals, Inc.	Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20
BR112014014276A2 (pt)	2011-12-12	2017-06-13	Dr Reddys Laboratories Ltd	composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor
CN104072498B (zh) *	2013-03-26	2016-12-28	沈阳药科大学	（R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
US10335494B2 (en)	2013-12-06	2019-07-02	Millennium Pharmaceuticals, Inc.	Combination of aurora kinase inhibitors and anti-CD30 antibodies
EP3157921A1 (fr)	2014-06-23	2017-04-26	Dr. Reddy's Laboratories Ltd.	Composés d'imidazo [1,2-a]pyridine substitués utiles pour le traitement de la douleur
US10273252B2 (en)	2015-06-15	2019-04-30	Ube Industries, Ltd.	Substituted dihydropyrrolopyrazole derivative
WO2017015316A1 (fr)	2015-07-21	2017-01-26	Millennium Pharmaceuticals, Inc.	Administration d'inhibiteur de kinase aurora et d'agents chimiothérapeutiques
CN107337674B (zh) *	2016-04-29	2019-09-20	江苏吉贝尔药业股份有限公司	用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
US11874276B2 (en)	2018-04-05	2024-01-16	Dana-Farber Cancer Institute, Inc.	STING levels as a biomarker for cancer immunotherapy
WO2021041532A1 (fr)	2019-08-26	2021-03-04	Dana-Farber Cancer Institute, Inc.	Utilisation d'héparine pour favoriser la signalisation de l'interféron de type 1
CN113563346A (zh) *	2021-08-19	2021-10-29	守恒(厦门)医疗科技有限公司	吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
EP4504710A1 (fr)	2022-04-07	2025-02-12	Eli Lilly and Company	Procédé de fabrication d'un inhibiteur de kras g12c
EP4504209A1 (fr)	2022-04-08	2025-02-12	Eli Lilly and Company	Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a
EP4547251A1 (fr)	2022-06-30	2025-05-07	Eli Lilly and Company	Inhibiteur de kras g12c pour le traitement du cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2717380B1 (fr) *	1994-03-15	1996-04-26	Oreal	Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en)	1999-05-12	1999-07-14	Pharmacia & Upjohn Spa	4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) *	1999-07-09	2001-01-11	Basf Ag	Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
WO2001012189A1 (fr)	1999-08-12	2001-02-22	Pharmacia Italia S.P.A.	Derives de 3(5)-amino-pyrazole, leur procede de fabrication et leur emploi comme agents anti-tumoraux
US6387900B1 (en)	1999-08-12	2002-05-14	Pharmacia & Upjohn S.P.A.	3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
JP4555547B2 (ja)	2000-08-10	2010-10-06	ファイザーイタリアソシエタアレスポンサビリタリミタータ	キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
FR2815032B1 (fr)	2000-10-10	2003-08-08	Pf Medicament	Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
AU2002215053A1 (en)	2000-11-27	2002-06-24	Pharmacia Italia S.P.A.	Phenylacetamido- pyrazole derivatives and their use as antitumor agents
CA2434066A1 (fr)	2001-01-26	2002-09-12	Pharmacia Italia S.P.A.	Derives de chromane, procede de preparation et d'utilisation de ces derives en tant qu'agents antitumoraux
CZ2004359A3 (cs)	2001-09-26	2004-09-15	Pharmacia Italia S.P.A.	Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty
CA2493625A1 (fr)	2002-07-25	2004-02-19	Pharmacia Italia S.P.A.	Bicyclo-pyrazoles actifs utiles comme inhibiteurs de kinase, leur procede de preparation et compositions pharmaceutiques les comprenant

2004
- 2004-07-01 US US10/882,493 patent/US7141568B2/en not_active Expired - Lifetime
- 2004-07-08 CA CA2531759A patent/CA2531759C/fr not_active Expired - Fee Related
- 2004-07-08 RS YUP-2006/0004A patent/RS20060004A/sr unknown
- 2004-07-08 KR KR1020067000310A patent/KR101075711B1/ko not_active Expired - Fee Related
- 2004-07-08 SI SI200431502T patent/SI1644376T1/sl unknown
- 2004-07-08 DK DK04763132.0T patent/DK1644376T3/da active
- 2004-07-08 AU AU2004255347A patent/AU2004255347B2/en not_active Ceased
- 2004-07-08 NZ NZ544514A patent/NZ544514A/xx not_active IP Right Cessation
- 2004-07-08 DE DE602004029045T patent/DE602004029045D1/de not_active Expired - Lifetime
- 2004-07-08 AP AP2006003480A patent/AP2214A/xx active
- 2004-07-08 GE GEAP20049209A patent/GEP20084395B/en unknown
- 2004-07-08 ME MEP-519/08A patent/MEP51908A/xx unknown
- 2004-07-08 TW TW093120474A patent/TWI343382B/zh not_active IP Right Cessation
- 2004-07-08 PT PT04763132T patent/PT1644376E/pt unknown
- 2004-07-08 PE PE2004000657A patent/PE20050325A1/es not_active Application Discontinuation
- 2004-07-08 WO PCT/EP2004/007515 patent/WO2005005427A1/fr not_active Ceased
- 2004-07-08 CN CNB2004800195930A patent/CN100564380C/zh not_active Expired - Fee Related
- 2004-07-08 RS RS20060004A patent/RS52155B/sr unknown
- 2004-07-08 MX MXPA06000362A patent/MXPA06000362A/es active IP Right Grant
- 2004-07-08 AT AT04763132T patent/ATE480540T1/de active
- 2004-07-08 ES ES04763132T patent/ES2349780T3/es not_active Expired - Lifetime
- 2004-07-08 BR BRPI0411868A patent/BRPI0411868B8/pt not_active IP Right Cessation
- 2004-07-08 EA EA200600209A patent/EA009462B1/ru not_active IP Right Cessation
- 2004-07-08 PL PL04763132T patent/PL1644376T3/pl unknown
- 2004-07-08 EP EP04763132A patent/EP1644376B1/fr not_active Expired - Lifetime
- 2004-07-08 JP JP2006518148A patent/JP4728232B2/ja not_active Expired - Fee Related
- 2004-07-09 GT GT200400133A patent/GT200400133A/es unknown
- 2004-07-09 DO DO2004000949A patent/DOP2004000949A/es unknown
- 2004-07-09 PA PA20048606201A patent/PA8606201A1/es unknown
- 2004-07-09 GT GT200400133AK patent/GT200400133AA/es unknown
- 2004-07-09 MY MYPI20042753A patent/MY139072A/en unknown
- 2004-07-09 HN HN2004000232A patent/HN2004000232A/es unknown
- 2004-07-12 AR ARP040102447A patent/AR050045A1/es active IP Right Grant
- 2004-08-07 UA UAA200601248A patent/UA81682C2/ru unknown
2005
- 2005-12-22 IS IS8192A patent/IS2843B/is unknown
- 2005-12-22 EC EC2005006246A patent/ECSP056246A/es unknown
- 2005-12-29 IL IL172923A patent/IL172923A/en active IP Right Grant
2006
- 2006-01-03 ZA ZA200600095A patent/ZA200600095B/en unknown
- 2006-01-05 CR CR8171A patent/CR8171A/es unknown
- 2006-01-06 NO NO20060113A patent/NO332361B1/no not_active IP Right Cessation
- 2006-01-09 TN TNP2006000009A patent/TNSN06009A1/fr unknown
- 2006-01-09 MA MA28721A patent/MA28064A1/fr unknown
- 2006-08-11 US US11/503,256 patent/US7582628B2/en not_active Expired - Lifetime
2010
- 2010-10-18 CY CY20101100924T patent/CY1110832T1/el unknown

Also Published As

Publication number	Publication date
DK1644376T3 (da)	2011-01-03
PL1644376T3 (pl)	2011-03-31
ES2349780T3 (es)	2011-01-11
NO20060113L (no)	2006-04-05
JP4728232B2 (ja)	2011-07-20
TW200510385A (en)	2005-03-16
IS2843B (is)	2013-08-15
MXPA06000362A (es)	2006-03-28
PT1644376E (pt)	2010-09-24
HN2004000232A (es)	2011-01-17
ECSP056246A (es)	2006-04-19
AU2004255347B2 (en)	2010-04-08
US20050032839A1 (en)	2005-02-10
ATE480540T1 (de)	2010-09-15
GEP20084395B (en)	2008-06-10
AU2004255347A1 (en)	2005-01-20
RS20060004A (sr)	2008-06-05
GT200400133A (es)	2005-04-18
EA009462B1 (ru)	2007-12-28
GT200400133AA (es)	2007-07-10
MEP51908A (en)	2011-05-10
AP2214A (en)	2011-03-04
PA8606201A1 (es)	2005-08-04
CY1110832T1 (el)	2015-06-10
BRPI0411868B1 (pt)	2019-11-12
ZA200600095B (en)	2007-01-31
US7582628B2 (en)	2009-09-01
EP1644376B1 (fr)	2010-09-08
CA2531759C (fr)	2013-04-02
NZ544514A (en)	2009-07-31
TNSN06009A1 (fr)	2007-10-03
JP2009513525A (ja)	2009-04-02
IS8192A (is)	2005-12-22
CA2531759A1 (fr)	2005-01-20
CN100564380C (zh)	2009-12-02
CN1820009A (zh)	2006-08-16
IL172923A0 (en)	2006-06-11
EP1644376A1 (fr)	2006-04-12
SI1644376T1 (sl)	2010-11-30
KR20060033001A (ko)	2006-04-18
EA200600209A1 (ru)	2006-06-30
DOP2004000949A (es)	2005-01-15
WO2005005427A1 (fr)	2005-01-20
RS52155B (sr)	2012-08-31
US20060276471A1 (en)	2006-12-07
MA28064A1 (fr)	2006-08-01
AP2006003480A0 (en)	2006-02-28
CR8171A (es)	2006-08-09
IL172923A (en)	2011-09-27
DE602004029045D1 (de)	2010-10-21
MY139072A (en)	2009-08-28
PE20050325A1 (es)	2005-05-17
BRPI0411868A (pt)	2006-08-08
BRPI0411868B8 (pt)	2021-05-25
AR050045A1 (es)	2006-09-27
UA81682C2 (en)	2008-01-25
US7141568B2 (en)	2006-11-28
TWI343382B (en)	2011-06-11
KR101075711B1 (ko)	2011-10-21
HK1089769A1 (en)	2006-12-08

Legal Events

Date	Code	Title	Description
2022-02-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
AU2004255347B2 (en)	2010-04-08	Pyrrolo(3,4-c)pyrazole derivatives active as kinase inhibitors
US8481584B2 (en)	2013-07-09	1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
JP5415271B2 (ja)	2014-02-12	キナーゼ阻害剤としての置換ピロロ−ピラゾール誘導体
EP1904503B1 (fr)	2013-11-06	Composes 1h-thieno[2,3-c]-pyrazole servant d'inhibiteurs de kinase
HK1089769B (en)	2010-08-27	Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors